Hemostatic Management of Extracorporeal Circuits Including Cardiopulmonary Bypass and Extracorporeal Membrane Oxygenation
- 13 December 2019
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 46 (01) , 062-072
Abstract
Cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO) cause hemostatic derangements that can predispose patients to both bleeding and thrombotic complications. Often, patients present for urgent surgery while taking medications including antiplatelet agents, vitamin K antagonists, and direct oral anticoagulants, which must be recognized, monitored, and managed. During extracorporeal circulation, appropriate anticoagulation, most commonly with heparin, is required to maintain blood flow and avoid thrombotic complications. However, anticoagulation and other effects of extracorporeal circuits can also have an undesired consequence of bleeding. Extracorporeal circulation leads to coagulopathy that may require therapy with blood products such as platelets, cryoprecipitate, and plasma in case a patient bleeds. Platelet dysfunction related to exposure to a foreign circuit is a primary concern, as is the development of acquired von Willebrand syndrome, which frequently remains undetected on routine testing. Hemorrhagic complications in ECMO, such as intracranial hemorrhage, pulmonary hemorrhage, and hemithorax, can occur. Hemostatic agents including antifibrinolytics, desmopressin, fibrinogen concentrates, and other factor concentrates may be needed to achieve hemostasis in these often-challenging patients. Managing bleeding on extracorporeal support requires careful monitoring and a thoughtful approach.Keywords
This publication has 84 references indexed in Scilit:
- Tranexamic acid concentrations associated with human seizures inhibit glycine receptorsJournal of Clinical Investigation, 2012
- ε-Aminocaproic Acid and Clinical Value in Cardiac AnesthesiaJournal of Cardiothoracic and Vascular Anesthesia, 2011
- Survival Time of ECMO Circuits On and Off Bleeding Protocol: Is there a Higher Risk of Circuit Clotting?European Journal of Pediatric Surgery, 2010
- Safety of Recombinant Activated Factor VII in Randomized Clinical TrialsNew England Journal of Medicine, 2010
- Factor Eight Inhibitor Bypassing Activity (FEIBA) for Refractory Bleeding in Cardiac Surgery: Review of Clinical OutcomesJournal of Cardiac Surgery, 2008
- Increased Plasma and Platelet to Red Blood Cell Ratios Improves Outcome in 466 Massively Transfused Civilian Trauma PatientsAnnals of Surgery, 2008
- The Effect of Surface Roughness on Activation of the Coagulation System and Platelet Adhesion in Rotary Blood PumpsArtificial Organs, 2007
- Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapyBlood Coagulation & Fibrinolysis, 2006
- Letter to the editor: Changes in fibrinolytic factors in newborns during extracorporeal membrane oxygenation (ECMO)American Journal of Hematology, 1991
- Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells.Journal of Clinical Investigation, 1984